|
CA2747703C
(en)
|
2009-01-06 |
2021-06-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention of infections by e. coli
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
EP2473487B1
(en)
|
2009-09-03 |
2016-10-26 |
Bristol-Myers Squibb Company |
Quinazolines as potassium ion channel inhibitors
|
|
US9511125B2
(en)
|
2009-10-21 |
2016-12-06 |
Curemark Llc |
Methods and compositions for the treatment of influenza
|
|
EP3239154A1
(en)
|
2011-01-10 |
2017-11-01 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
GB201114212D0
(en)
*
|
2011-08-18 |
2011-10-05 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2013068592A1
(en)
*
|
2011-11-10 |
2013-05-16 |
Fondation Jerome Lejeune |
Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide
|
|
AR090037A1
(es)
|
2011-11-15 |
2014-10-15 |
Xention Ltd |
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
|
|
TW201728592A
(zh)
*
|
2012-01-10 |
2017-08-16 |
林伯士艾瑞斯公司 |
Ｉｒａｋ抑制劑及其用途
|
|
WO2013112706A1
(en)
*
|
2012-01-25 |
2013-08-01 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating compounds
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP2671575A1
(en)
*
|
2012-06-04 |
2013-12-11 |
Universität Regensburg |
Ras inhibitors
|
|
PT2858987T
(pt)
|
2012-06-11 |
2018-07-04 |
Bristol Myers Squibb Co |
Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida
|
|
HK1210732A1
(en)
|
2012-07-11 |
2016-05-06 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2872144A4
(en)
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
JP6318156B2
(ja)
*
|
2012-09-06 |
2018-04-25 |
プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． |
キナーゼをモジュレートするための化合物および方法、ならびにその指標
|
|
JP6535430B2
(ja)
*
|
2012-09-28 |
2019-06-26 |
イグニタ、インク． |
非定型プロテインキナーゼｃのアザキナゾリン阻害薬
|
|
GB201217704D0
(en)
*
|
2012-10-03 |
2012-11-14 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US20140136295A1
(en)
|
2012-11-13 |
2014-05-15 |
Apptio, Inc. |
Dynamic recommendations taken over time for reservations of information technology resources
|
|
WO2014110114A1
(en)
|
2013-01-10 |
2014-07-17 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2956470A4
(en)
*
|
2013-02-15 |
2016-12-07 |
Univ Michigan Regents |
COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS
|
|
AU2014249233A1
(en)
*
|
2013-03-13 |
2015-09-24 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
CN104119343A
(zh)
*
|
2013-04-25 |
2014-10-29 |
苏州科捷生物医药有限公司 |
2-三氟甲基噻二唑类化合物及其用途
|
|
EP3049086A4
(en)
|
2013-09-27 |
2017-02-22 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
TWI648281B
(zh)
|
2013-10-17 |
2019-01-21 |
日商安斯泰來製藥股份有限公司 |
含硫二環式化合物
|
|
JP2017001954A
(ja)
*
|
2013-11-08 |
2017-01-05 |
石原産業株式会社 |
含窒素飽和複素環化合物
|
|
CN104892589A
(zh)
*
|
2014-03-07 |
2015-09-09 |
中国科学院上海药物研究所 |
一类杂环化合物、其制备方法和用途
|
|
EP3116867A4
(en)
*
|
2014-03-11 |
2017-10-18 |
Godavari Biorefineries Ltd. |
Cancer stem cell targeting compounds
|
|
USRE49687E1
(en)
|
2014-09-09 |
2023-10-10 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
US10526341B2
(en)
|
2014-11-19 |
2020-01-07 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
|
CN104592248A
(zh)
*
|
2014-12-31 |
2015-05-06 |
芜湖杨燕制药有限公司 |
一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法
|
|
TWI703150B
(zh)
*
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
|
|
WO2016197027A1
(en)
|
2015-06-04 |
2016-12-08 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
AU2017212572A1
(en)
|
2016-01-26 |
2018-08-23 |
Memorial Sloan-Kettering Cancer Center |
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
|
|
WO2017161028A1
(en)
*
|
2016-03-16 |
2017-09-21 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-mll and methods of use
|
|
US10752639B2
(en)
|
2016-03-16 |
2020-08-25 |
Kura Oncology, Inc. |
Bridged bicyclic inhibitors of menin-MLL and methods of use
|
|
CN109415337B
(zh)
|
2016-05-02 |
2022-01-18 |
密执安大学评议会 |
作为多发性内分泌腺瘤蛋白抑制剂的哌啶
|
|
WO2017207387A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
|
|
WO2018024602A1
(en)
|
2016-08-04 |
2018-02-08 |
Bayer Aktiengesellschaft |
2,7-diazaspiro[4.4]nonanes
|
|
TWI753016B
(zh)
|
2016-09-14 |
2022-01-21 |
比利時商健生藥品公司 |
Menin-mll相互作用之稠合二環抑制劑
|
|
US12084462B2
(en)
|
2016-09-14 |
2024-09-10 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
AU2017326487B2
(en)
|
2016-09-14 |
2021-08-05 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
CA3033239A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
MX2019004950A
(es)
|
2016-10-28 |
2019-09-26 |
Icahn School Med Mount Sinai |
Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
|
|
CA3045037A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
KR102513564B1
(ko)
*
|
2016-12-15 |
2023-03-22 |
얀센 파마슈티카 엔.브이. |
메닌-mll 상호작용의 아제판 억제제
|
|
EA201991448A1
(ru)
|
2017-01-06 |
2019-12-30 |
Янссен Фармацевтика Нв |
Азепановые ингибиторы взаимодействия менин-mll
|
|
EA038388B1
(ru)
*
|
2017-01-16 |
2021-08-19 |
Кура Онколоджи, Инк. |
Замещенные ингибиторы менина-mll и способы применения
|
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
EP3600313A4
(en)
|
2017-03-31 |
2020-09-23 |
The Regents of The University of Michigan |
PIPERIDINES AS COVALENT MENINE INHIBITORS
|
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
|
TW201920170A
(zh)
|
2017-09-20 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
經取代之menin-mll 抑制劑及使用方法
|
|
US11396517B1
(en)
|
2017-12-20 |
2022-07-26 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-MLL interaction
|
|
JP7307729B2
(ja)
|
2017-12-20 |
2023-07-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
|
|
JP2021515013A
(ja)
|
2018-03-06 |
2021-06-17 |
アイカーン スクール オブ メディスン アット マウント シナイ |
セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
|
|
CN112105621B
(zh)
|
2018-03-30 |
2024-02-20 |
住友制药株式会社 |
光学活性桥型环状仲胺衍生物
|
|
JP2021527666A
(ja)
|
2018-06-21 |
2021-10-14 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
|
|
WO2020010204A1
(en)
|
2018-07-05 |
2020-01-09 |
Icahn School Of Medicine At Mount Sinai |
Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
|
|
EP3860978A1
(en)
|
2018-10-03 |
2021-08-11 |
The Regents Of The University Of Michigan |
Small molecule menin inhibitors
|
|
CN114423463B
(zh)
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
CN112574224A
(zh)
*
|
2019-09-30 |
2021-03-30 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
TW202126636A
(zh)
|
2019-09-30 |
2021-07-16 |
美商阿吉歐斯製藥公司 |
作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
|
|
UY38988A
(es)
|
2019-12-19 |
2021-06-30 |
Janssen Pharmaceutica Nv |
Derivados espiráncos sustituidos de cadena lineal
|
|
CN111297863B
(zh)
*
|
2020-03-30 |
2021-06-25 |
四川大学华西医院 |
menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
|
|
TW202204334A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
|
WO2021204159A1
(en)
|
2020-04-08 |
2021-10-14 |
Agios Pharmaceuticals, Inc. |
Menin inhibitors and methods of use for treating cancer
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20230391765A1
(en)
*
|
2020-10-21 |
2023-12-07 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of enl
|
|
BR112023021040A2
(pt)
|
2021-05-08 |
2024-02-06 |
Janssen Pharmaceutica Nv |
Derivados espiro substituídos
|
|
EP4334310A1
(en)
|
2021-05-08 |
2024-03-13 |
JANSSEN Pharmaceutica NV |
Substituted spiro derivatives
|
|
CA3218479A1
(en)
|
2021-06-01 |
2022-12-08 |
Wei Cai |
Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
|
|
WO2022253289A1
(en)
|
2021-06-03 |
2022-12-08 |
Janssen Pharmaceutica Nv |
Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
|
|
AU2022292697A1
(en)
|
2021-06-17 |
2024-02-01 |
Janssen Pharmaceutica Nv |
(r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
|
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
|
US20260151399A1
(en)
|
2022-11-24 |
2026-06-04 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
|
|
AR132185A1
(es)
|
2023-03-24 |
2025-06-04 |
Acerta Pharma Bv |
COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
|